Table of Contents
<< Previous Issue | Jul 2020 (Vol: 2020, Issue: 7) | Next Issue >> |
- Section: Licensing
-
Neurocrine Biosciences Licenses Seven Psychiatric Programmes from Takeda in US$2 B Deal
-
CSL Behring Licenses Phase III Haemophilia B Gene Therapy Candidate from uniQure
-
AstraZeneca Signs US$6 B ADC Collaboration with Daiichi Sankyo for DS-1062
-
Roche and Blueprint Medicines Partner Again in US$1.7 B Pralsetinib Pact
- Section: Research & Development
-
Sanofi Expands mRNA Collaboration with Translate Bio
-
GlaxoSmithKline Partners with CureVac to Develop mRNA-based Vaccines